This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peacey, S. R. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Peacey, S. R. Articles by Shalet, S. M.

Hypothalamic Dysfunction in "Cured" Acromegaly Is Treatment Modality Dependent

Department of Endocrinology, Christie Hospital, Manchester, United Kingdom M20 4BX

Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital, Wilmslow Road, Manchester, United Kingdom M20 4BX.

The current definition of cure after treatment for acromegaly stipulates a reduction in GH levels to less than 2 ng/mL (<5 mU/L), as such GH concentrations are believed to be associated with normalization of long term survival. We sought to further define the nature of the cure in such patients, when cure has been achieved by alternative therapeutic modalities, in the expectation that hypothalamic neuroregulatory control of GH secretion might be affected differently by radiotherapy or surgery. In particular we wished to determine the effect of therapy modality on endogenous somatostatin (SMS) tone, using the GH response to iv arginine as a paradigm. We studied 20 patients with cured acromegaly (mean 24-h GH concentration, <2 ng/mL). Eight patients had been cured by surgery only (S; 4 women and 4 men; mean ± SEM age, 52 ± 5 yr), and 12 patients had been cured by radiotherapy (R; 4 women and 8 men; age, 52 ± 3 yr). Sixteen healthy subjects were studied as a control group (C; 6 women and 10 men; age 53 ± 3]. The median (range) GH during 24-h profiles was similar in each group: S, 1.3 (0.7–1.8) ng/mL; R, 0.6 (0.4–1.8) ng/mL; and C, 0.7 (0.4–3.2) ng/mL (P = 0.57). The median incremental GH responses to arginine were significantly lower in the R group compared with those in the S and C groups: S, 6.4 (2.1–16.6) ng/mL; R, 0.1 (0–1.7) ng/mL; and C, 9.2 (0–16.1) ng/mL (P = 0.0002; S vs. R, P < 0.01; S vs. C, P > 0.05; R vs. C, P < 0.001). We conclude that in acromegalic patients deemed to be cured (GH, <2 ng/mL), the mode of therapy has considerable influence on the remaining hypothalamic-somatotroph function. In view of the putative mechanism by which arginine releases GH, we suggest that radiotherapy leads to a reduction or complete loss of endogenous SMS tone. This may have implications for the treatment of those acromegalic patients who are not cured (GH, >2 ng/mL) and who require SMS analog therapy.

This article has been cited by other articles:

				M. Losa, L. Gioia, P. Picozzi, A. Franzin, M. Valle, M. Giovanelli, and P. Mortini The Role of Stereotactic Radiotherapy in Patients with Growth Hormone-Secreting Pituitary Adenoma J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2546 - 2552. [Abstract] [Full Text] [PDF]

				C. Parkinson, P. Burman, M. Messig, and P. J. Trainer Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 190 - 195. [Abstract] [Full Text] [PDF]

				J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, P. M. Stewart, and A. S. Bates Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1613 - 1617. [Abstract] [Full Text] [PDF]

				P. U. Freda, A. T. Nuruzzaman, C. M. Reyes, R. E. Sundeen, and K. D. Post Significance of "Abnormal" Nadir Growth Hormone Levels after Oral Glucose in Postoperative Patients with Acromegaly in Remission with Normal Insulin-Like Growth Factor-I Levels J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 495 - 500. [Abstract] [Full Text] [PDF]

				S. R. Peacey, A. A. Toogood, J. D. Veldhuis, M. O. Thorner, and S. M. Shalet The Relationship between 24-Hour Growth Hormone Secretion and Insulin-Like Growth Factor I in Patients with Successfully Treated Acromegaly: Impact of Surgery or Radiotherapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 259 - 266. [Abstract] [Full Text]

				J. S. Powell, S. L. Wardlaw, K. D. Post, and P. U. Freda Outcome of Radiotherapy for Acromegaly Using Normalization of Insulin-Like Growth Factor I to Define Cure J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2068 - 2071. [Abstract] [Full Text]

				H.E. Turner and J.A.H. Wass Modern approaches to treating acromegaly QJM, January 1, 2000; 93(1): 1 - 6. [Full Text] [PDF]

				P. U. Freda, K. D. Post, J. S. Powell, and S. L. Wardlaw Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3808 - 3816. [Abstract] [Full Text]